OpenAI Acquires Orchestra Bio to Fold Agentic Drug-Program Layer Into Rosalind Life Sciences Suite

OpenAI is acquiring Orchestra Bio, whose 'agentic operating layer' lets scientists and AI agents jointly manage drug programs — monitoring studies, tracking timelines, and flagging delays. The team and tech will be folded into OpenAI's Rosalind life-sciences suite (launched this month with a 30-seat academic plan); financial terms were not disclosed.